1. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
- Author
-
Rini, Brian, Abel, E. Jason, Albiges, Laurence, Bex, Axel, Brugarolas, James, Bukowski, Ronald M., Coleman, Jonathan A., Drake, Charles G., Figlin, Robert A., Futreal, Andy, Hammers, Hans, Powles, Thomas, Rathmell, W. Kimryn, Ricketts, Christopher J., Turajlic, Samra, Wood, Christopher G., and Leibovich, Bradley C.
- Subjects
RENAL cell carcinoma ,CANCER immunotherapy ,PATHOLOGIC complete response ,BIOMARKERS - Abstract
Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural "Think Tank: Coalition for a Cure" session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF